NCT06941025View on ClinicalTrials.gov

Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding

Not yet recruitingOBSERVATIONAL
Enrollment

10

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

December 31, 2034

Study Completion Date

December 31, 2034

Conditions
Fabry DiseasePregnancyPregnancy Complications
Interventions
OTHER

Not applicable- observational study

Not applicable - observational study

Trial Locations (5)

20001

No physical study sites - Decentralized, web-based registry, Washington D.C.

Unknown

No physical study sites - Decentralized, web-based registry, Berlin

No physical study sites - Decentralized, web-based registry, Rome

No physical study sites - Decentralized, web-based registry, Madrid

No physical study sites - Decentralized, web-based registry, London

Sponsors

Collaborators (1)

ICON plc
All Listed Sponsors
collaborator

ICON plc

INDUSTRY

lead

Chiesi Farmaceutici S.p.A.

INDUSTRY

NCT06941025 - Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding | Biotech Hunter | Biotech Hunter